🇺🇸 FDA

Intelligence Platform

Patents

Browse 912 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12203098

Cells having solid tumor targeting backbone and use thereof

Fate Therapeutics, Inc. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12195724

Methods of producing T cell populations enriched for stable regulatory T-cells

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12188005

NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12187780

Car t-cells comprising inactivated CBL and CBL-B genes

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12187777

Engineered invariant natural killer T (iNKT) cells and methods of making and using thereof

The Regents of the University of California · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180509

Methods for reprograming non-pluripotent cells into pluripotent stem cells

BeiHao Stem Cell and Regenerative Medicine Research Institute Co., Ltd. · Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12173317

Use of histone modifiers to reprogram effector T cells

The Board of Regents of the University of Texas System · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12173324

Differentiation of pancreatic endocrine cells

Vertex Pharmaceuticals Incorporated · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12171818

Methods of isolating T cells having antigenic specificity for a cancer-specific mutation

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12171785

Pluripotent cells derived from bone marrow and methods for isolation

Regents of the University of Minnesota · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12173274

Enhanced immune effector cells and use thereof

Fate Therapeutics, Inc. · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12171786

Use of mesenchymal stem cells for the treatment of inflammation

The Regents of the University of California · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12170134

Systems and methods for coordinating manufacturing of cells for patient-specific immunothe

Iovance Biotherapeutics, Inc. · Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12161674

CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof

Vertex Pharmaceuticals Incorporated · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12163153

Methods of manufacturing allogeneic CAR T cells

Allogene Therapeutics, Inc. · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12157778

Peptides for activation of cell signaling in osteoprogenitor cells

The Regents of the University of California · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12159700

Systems and methods for coordinating manufacturing of cells for patient-specific immunothe

Iovance Biotherapeutics, Inc. · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12139522

T-cells comprising two different chimeric antigen receptors and uses thereof

THE MEDICAL RESEARCH INFRASTRUCTURE AND HEAL SERVICED FUND OF THE TEL AVIV MEDECAL CENTER · Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12109239

Methods for production of human hemogenic endothelial cells from pluripotent stem cells an

Astellas Institute for Regenerative Medicine · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12109236

Manipulating ARID5B expression in immune cells to promote metabolism, survival, and functi

Regents of the University of Minnesota · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12104172

Processes for generating TIL products enriched for tumor antigen-specific t-cells

Iovance Biotherapeutics, Inc. · Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12097223

Mesenchymal stromal cells and uses related thereto

Astellas Institute for Regenerative Medicine · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12098182

Polypeptides, cells, and methods involving engineered CD16

Regents of the University of Minnesota · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12083191

Composition and methods for imaging cells

Northwestern University · Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted